Vir Biotechnology Inc. (VIR) Reports Data Suggesting Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2
Get Alerts VIR Hot Sheet
Join SI Premium – FREE
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that preclinical data suggest that sotrovimab, an investigational monoclonal antibody authorized for emergency use in the United States and developed in conjunction with GlaxoSmithKline, retains neutralizing activity against the BA.2 subvariant of Omicron. These pseudovirus results are being shared with government and regulatory authorities around the world and the Company expects to publish data on bioRxiv in the coming week, with live virus data to follow.
“Our view of the data is that they support the ongoing role of sotrovimab as a critical treatment in the fight against the continuously evolving SARS-CoV-2 virus,” said George Scangos, Vir’s chief executive officer. “We note recent conclusions from another lab, which state that no approved or authorized monoclonal antibodies for treatment retain activity against all subvariants of Omicron. We are therefore pleased to share that, based on our pseudovirus and extensive pharmacokinetic data, we believe that the 500 mg dose of sotrovimab is sufficient to retain activity against the BA.2 variant, just as it has against all other variants of concern and interest.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crinetics Pharmaceuticals (CRNX) Reports paltusotine met Primary and All Secondary Endpoints
- Citius Pharmaceuticals (CTXR) Announces FDA Acceptance of BLA Resubmission of LYMPHIR for Treatment of Adults with R/R Cutaneous T-Cell Lymphoma
- Delcath Systems (DCTH) Appoints Martha S. Rook as Chief Operating Officer
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!